Peripheral ulcerative keratitis and corneal melt: A 10-year single center review with historical comparison

Cornea

Volumn 33, Issue 1, 2014, Pages 27-31

  Knox Cartwright, Nathaniel E ^a   Tole, Derek M ^a   Georgoudis, Panagiotis ^a   Cook, Stuart D ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

corneal perforation; corneal ulcer; keratitis; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGIC GLUE; CORTICOSTEROID; CYANOACRYLATE; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS;

AGED; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA PERFORATION; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KERATITIS; MAJOR CLINICAL STUDY; MONOTHERAPY; OPHTHALMIC ARGON LASER; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TACHYCARDIA; TRABECULOPLASTY; ULCERATIVE KERATITIS; VISUAL ACUITY; ADULT; AUTOIMMUNE DISEASE; COMPLICATION; CORNEAL ULCER; DRUG COMBINATION; FEMALE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; UNITED KINGDOM; VERY ELDERLY;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CORNEAL ULCER; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VISUAL ACUITY;

EID: 84890433943     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000008     Document Type: Review

References (16)

1. McKibbin M, Isaacs JD, Morrell AJ. Incidence of corneal melting in association with systemic disease in the Yorkshire region, 1995-7. Br J Ophthalmol. 1999;83:941-943
2. Tauber J, Sainz de la Maza M, Hoang-Xuan T, et al. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea. 1990;9:66-73
3. Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am. 2007;33:835-854, vii
4. Squirrell D, Winfield J, Amos RS. Peripheral ulcerative keratitis "corneal melt" and rheumatoid arthritis: A case series. Rheumatology (Oxford). 1999;38:1245-1248
5. Ladas JG, Mondino BJ. Systemic disorders associated with peripheral corneal ulceration. Curr Opin Ophthalmol. 2000;11:468-471
6. McNab AA, Potts MJ, Welham RA. The EEC syndrome and its ocular manifestations. Br J Ophthalmol. 1989;73:261-264
7. Goldsmith A. The ocular manifestations of rosacea. Br J Dermatol. 1953; 65:448-457
8. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984;91:1253-1263
9. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999;43:379-396
10. Malik R, Culinane AB, Tole DM, et al. Rheumatoid keratolysis: A series of 40 eyes. Eur J Ophthalmol. 2006;16:791-797
11. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-2219
12. Resman-Targoff BH, Cicero MP. Aggressive treatment of early rheumatoid arthritis: Recognizing the window of opportunity and treating to target goals. Am J Manag Care. 2010;16:S249-S258
13. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30:287-290
14. Tervaert JW, Popa ER, Bos NA. The role of superantigens in vasculitis. Curr Opin Rheumatol. 1999;11:24-33
15. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416-1421, 1421 e1
16. Schiff M, Beaulieu A, Scott DL, et al. Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: Three 24-week, randomized, double-blind, placebo-or ciclosporin-controlled trials. Clin Drug Investig. 2010;30:613-624